Background: Predicting acute renal failure in patients with severe sepsis is important, because patients may need renal replacement therapy (RRT). Neutrophil gelatinase-associated lipocalin (NGAL) has been evaluated for its ability to detect and predict acute kidney injury (AKI) in critically ill patients. This study aimed to assess the predictive value of plasma NGAL for acute renal failure in adult severely septic patients. Methods: Thirty healthy adults and 85 adult patients admitted to the medical intensive care unit (ICU) were enrolled. Serum creatinine, plasma NGAL, and interleukin (IL)-6, IL-10, and IL-17 levels were evaluated. AKI was classified as Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE). Results: RIFLE-Failure (RIFLE-F) developed in 30 of 76 (39.5%) patients with severe sepsis without chronic kidney disease within 7 days after ICU admission. Serum creatinine, plasma NGAL, IL-6, and IL-10 could predict RIFLE-F within 7 days after ICU admission. The discriminatory power of plasma NGAL was not significant for predicting hospital mortality. The area under the receiver operating characteristic curve of plasma NGAL was not higher than that of serum creatinine in predicting RIFLE-F within 7 days. Conclusion: Plasma NGAL is a useful tool for predicting acute renal failure in adult patients with severe sepsis. Serum creatinine has a similar ability to detect RIFLE-F occurrence.
Introduction
Sepsis is a leading cause of acute kidney injury (AKI) in critically ill patients. 1, 2 AKI is an important issue that increases mortality among patients with severe sepsis. 3 In current clinical practice, the proportional change of serum creatinine is the most common indicator of renal dysfunction. However, its slow rate of change has limited its application for diagnosing and predicting AKI. 4e6 Recently, several studies have investigated the early detection and prediction of AKI by neutrophil gelatinase-associated lipocalin (NGAL) as a novel biomarker, 4 ,6e11 although NGAL from activated neutrophils is also a marker of infection and systemic inflammation. When severe sepsis is complicated by AKI, the predictive performance of NGAL may be affected.
Sepsis is a complicated syndrome in which proinflammatory cytokines like interleukin (IL)-6 and antiinflammatory cytokines like IL-10 are expressed simultaneously. 15 Previous studies have shown that elevated levels of Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.such cytokines predict AKI development and mortality in patients with sepsis and AKI.
16e18 IL-17 is reported to play a role in the pathogenesis of AKI. 19 Can IL-6, IL-10, and IL-17 also be useful markers for acute renal failure in patients with severe sepsis?
The optimal timing for initiating renal replacement therapy (RRT) for AKI in patients with severe sepsis has not been established. The Acute Dialysis Quality Initiative (ADQI) proposed a consensus definition for the Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease (RIFLE) classification for AKI, grading severity by risk, injury, and failure. 20 Two studies suggested that early RRT prior to RIFLE-Failure (F) stage may improve the outcome of AKI patients who need RRT. 21, 22 Promising AKI biomarkers to predict RIFLE-F may allow for the optimal timing of initiating RRT.
The main purpose of this study was to evaluate the potential for plasma NGAL and cytokines to predict RIFLE-F and RRT initiation in patients with severe sepsis.
Methods

Participants
This was a prospective observational study of 115 patients who had undergone tests for plasma neutrophil gelatinaseassociated lipocalin (NGAL) and cytokines. Seventy-six adult patients did not have a history of chronic kidney disease (CKD) or end-stage renal disease. CKD was defined as decreased kidney function (estimated glomerular filtration rate < 60 mL/min/1.73 m 2 ) for ! 3 months. 23 Nine patients had end-stage renal disease (RIFLE-E) and received regular hemodialysis. These 85 patients were admitted to the medical intensive care unit (ICU) at Chang Gung Memorial Hospital in Keelung, Taiwan due to severe sepsis from July 2008 to August 2010. Thirty healthy adults were recruited from the hospital's health evaluation center (Fig. 1) . The ICU was a closed-format unit staffed by medical intensivists. The hospital's Institutional Review Board approved the study (99-2232B), and the patients' families provided informed consent.
Clinical data collection and definitions
Within the first 24 hours of admission, data on patients' age, gender, medical history, infection source, and comorbidity were recorded. Standard treatment, including fluid resuscitation, broad-spectrum antibiotics, drainage, and basic support were provided to all patients. 24 Antibiotics and fluid resuscitation were started as soon as possible after sepsis was diagnosed.
Severe sepsis and septic shock were defined according to the criteria of the Consensus Conference. 25 Systemic inflammatory response syndrome (SIRS) was defined as two or more of the following criteria: (1) body temperature > 38 C or < 36 C; (2) respiratory rate > 24 breaths/min; (3) heart rate > 90 beats/min; and (4) white blood count > 12,000/mL or < 4000/mL or > 10% bands. Sepsis was defined as SIRS based on confirmed or suspected microbial etiology, while severe sepsis was defined as sepsis with one or more of organ dysfunction or with hypotension. Septic shock was defined as sepsis with hypotension unresponsive to fluid resuscitation and further requiring vasopressors to maintain blood pressure on admission day. Survivors were defined as patients who were still alive 28 days after ICU admission. Disease severity was assessed by the Acute Physiology and Chronic Health Evaluation (APACHE) II score using data within 24 hours of admission. 26 AKI was defined using serum creatinine and urine output criteria to determine the RIFLE classification of all patients. The criteria that led to the worst possible classification were used. Because some patients (n ¼ 8, 10.5%) did not have baseline renal function, a hypothetical baseline serum creatinine was estimated for a given patient assuming a normal glomerular filtration rate (75 mL/min per 1.73 m 2 ) with modification of diet in renal disease (MDRD) formula, as recommended by the ADQI working group. 
NGAL and cytokine measurements
Plasma samples were obtained from veins within 24 hours after admission to the medical ICU. All plasma samples were stored at À80 C until centrifugation within 2 hours. Plasma levels of IL-6, IL-17, and NGAL were measured by human IL-6, IL-17, and NGAL enzyme-linked immunosorbent assay (ELISA) kits (R & D Systems, Minneapolis, MN, USA). Plasma level of IL-10 was measured by human IL-10 ELISA kit (Pierce Biotechnology, Rockford, IL, USA).
Statistical analysis
Statistical analysis was performed using SPSS for Windows version 17.0 (SPSS Inc., Chicago, IL, USA). Differences in age, APACHE II score, serum creatinine, cytokine level, and plasma NGAL between the two groups were analyzed by ManneWhitney U test. Differences in categorical variables such as gender, medical history, comorbidity, and mortality between the two groups were compared using c 2 test or Fisher's exact test. Area under the receiver operating characteristic curve (AUROC) was calculated to analyze the discriminatory power of predictive accuracy for RIFLE-F, RRT, and mortality. An appropriate cutoff value of plasma NGAL (150 ng/mL) was chosen according to meta-analysis of the available NGAL studies. 27 Reasonable cutoff values of cytokines were chosen according to the ROC analysis of healthy adults and patients with RIFLE-E. Sensitivity and specificity were defined as the proportion of patients correctly identified by the test as abnormal and the proportion of negatives correctly identified, respectively. Positive predictive value (PPV) was the proportion of patients with RIFLE-F within 7 days among those with positive test results. The negative predictive value (NPV) was the proportion of patients without RIFLE-F within 7 days among those with negative test results. For positive test results, the likelihood ratio was the odds of positive test results in patients with RIFLE-F within 7 days, versus positive test results in patients without RIFLE-F within 7 days. For negative test results, the likelihood ratio was the odds of negative test results in patients without RIFLE-F within 7 days, versus negative test results in patients with RIFLE-F within 7 days. A value of p < 0.05 was considered statistically significant.
Results
The clinical characteristics and biomarkers of 76 patients with severe sepsis without chronic kidney disease are shown in Table 1 . The power of the sample size for plasma NGAL and serum creatinine, IL-6, IL-10, and IL-17 was 98%, 100%, 77%, 91%, and 7%, respectively.
Comparison of non-RIFLE-F and RIFLE-F
In the 76 patients with severe sepsis, 30 (39.5%) had RIFLE-F within 7 days after ICU admission. Serum creatinine and plasma NGAL, IL-6, and IL-10 levels in RIFLE-F patients were significantly higher than in non-RIFLE-F patients. The APACHE II score and mortality within 28 days showed significant differences between RIFLE-F and non-RIFLE-F patients. There were no significant differences in age, sex, and history (except liver cirrhosis) between RIFLE-F and non-RIFLE-F patients. The proportions of septic shock, bacteremia, jaundice, and thrombocytopenia were significantly higher in RIFLE-F patients compared to non-RIFLE-F patients.
Comparison of biomarkers for predicting RIFLE-F and death
Serum creatinine (area under ROC curve ¼ 0.894, p < 0.001) and plasma IL-10 (AUROC ¼ 0.818, p < 0.001) had good discriminatory power for predicting RIFLE-F within 7 days (Fig. 2 and Table 2 ). Plasma NGAL (AUROC ¼ 0.731, p ¼ 0.001) showed fair discrimination for predicting RIFLE-F after ICU admission.
The demographic data of healthy controls and patients with severe sepsis with RIFLE-E are shown in Table 3 . A reasonable cutoff value was chosen according to the ROC analysis of the two groups. These cutoff values were used to predict the development of RIFLE-F. Table 4 lists the calculated sensitivity, specificity, PPV, NPV, likelihood ratio of positive test, and likelihood ratio of negative test with the cutoff concentrations of plasma NGAL, serum creatinine, IL-6, and IL-10 levels for the prediction of RIFLE-F within 7 days.
We also analyzed mortality within 28 days by the biomarkers (Table 5) . Plasma IL-6 yielded an AUROC of 0.699 ( Fig. 3 and Table 6 ). Both serum creatinine and IL-10 could significantly predict hospital mortality, but their discriminatory power was poor. Plasma NGAL had no value in predicting patient mortality.
Discussion
Plasma NGAL has been investigated in various settings of AKI, such as after cardiac surgery, 4, 6 in patients receiving intravenous contrast media infusion, 7, 8 and in critically ill patients. 9 ,11 It appears to be a promising biomarker, especially in the pediatric population. 6, 8, 11 In contrast to pediatric patients, the adult population has a proportion of comorbidities and underlying CKD. The timing and severity of renal insult are known in those patients with surgery and intravenous contrast exposure but are difficult to determine during sepsis.
This observational study evaluated the predictive value of plasma NGAL for acute renal failure in adult patients with severe sepsis and found that plasma NGAL levels were significantly higher in patients with RIFLE-F compared to non-RIFLE-F patients. Plasma NGAL had fair discriminatory power to predict RIFLE-F but did not have good prognostic value for clinical outcomes. Plasma NGAL was not superior to serum creatinine in the prediction of RIFLE-F within 7 days in patients with severe sepsis.
In the current study, prediction of the development of RIFLE-F by plasma NGAL was similar to that by serum creatinine, which is consistent with results of the study by de Geus et al 28 performed in 632 patients upon ICU admission. In Table 3 Demographic data of healthy controls and severely septic patients with RIFLE-E.
Age (y) 60.7 ± 1.9 67.7 ± 3.6 Male sex* 22 (73.3) 2 (22.2) Plasma NGAL (ng/mL)* 74.8 ± 6.0 494.8 ± 44.8 Serum Cr (mg/dL)* 0.9 ± 0.0 5.2 ± 1.2 Plasma IL-6 (pg/mL)* 3.7 ± 2.1 209.9 ± 60.8 Plasma IL-10 (pg/mL)* 6.7 ± 1.8 89.9 ± 35.7 Plasma IL-17 (pg/mL) 1.1 ± 0.6 4.4 ± 3.8
Data are presented as mean ± standard error or n (%). *p < 0.05. Cr ¼ creatinine; IL ¼ interleukin; NGAL ¼ neutrophil gelatinase-associated lipocalin; RIFLE-E ¼ End-stage kidney disease of Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease classification.
that study, serum creatinine-derived estimated glomerular filtration rate had similar predictive accuracy for AKI in ICU patients compared to plasma NGAL, even though patients with sepsis only accounted for 6.8% (43/632). Martensson et al 29 also reported that plasma NGAL was a poor predictor (AUROC ¼ 0.67) for AKI in patients with septic shock. Possible explanations include the unknown timing of renal insult and the influence of the inflammatory state on plasma NGAL production. Sepsis is a major precipitating factor for AKI in critically ill patients.
1,2 Plasma NGAL increases within 2 hours after acute tubular damage, 6, 30 but serum creatinine has a slow rate of change of 24e72 hours following renal injury. 4, 6 Nevertheless, the timing of renal insult in patients with severe sepsis cannot be identified clearly. Thus, plasma NGAL is not superior in predictive value over serum creatinine in ICU patients. NGAL is secreted from activated neutrophils and expressed in organs containing epithelial tissues, including the lungs, liver, kidney, and gastrointestinal tract. 13, 31, 32 There are high concentrations of NGAL in plasma when acute tubular damage develops. 6, 30 Moreover, NGAL is also expressed in high concentrations during inflammation or infection, including sepsis and malignancy. 29, 33 Therefore, plasma NGAL may have higher expression not only in renal tubular damage but also in severe sepsis. This may influence its diagnostic and predictive value for acute renal failure in patients with severe sepsis.
This study used IL-6 and IL-10 as reference markers of sepsis with acute renal failure. Early inflammatory response in sepsis is characterized by the release of several proinflammatory cytokines, including IL-6, 15,34 although its role in AKI is not well characterized. To date, elevated IL-6 levels might predict sustained AKI after ischemic injury in renal allografts. 35 Simmons et al 17 reported that increased IL-6 levels would predict mortality in patients with sepsis and AKI. In the present study, IL-6 level was significantly higher in RIFLE-F patients than in non-RIFLE-F patients. Similarly, elevated concentrations of IL-6 could predict AKI in placebotreated patients with severe sepsis in the PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) study. 16 In this study, plasma IL-10 level showed significant difference between RIFLE-F and non-RIFLE-F groups in patients with severe sepsis. This was similar to the study of Ahlstr€ om et al, 18 in which patients with acute renal failure showed significantly higher plasma levels of IL-10 than patients without acute renal failure. Although IL-17 is involved in the pathogenesis of AKI, plasma IL-17 levels were not associated with RIFLE-F development within 7 days and 28-day mortality.
There was one limitation to this study. The RIFLE classification is recommended to define and stage AKI in clinical studies. Baseline serum creatinine should be known, but some patients did not have available baseline serum creatinine for calculation of the proportional decrease of renal function. Thus, an estimated baseline serum creatinine, based on the MDRD equation proposed by the ADQI in previous studies, was used. 36, 37 This may have overestimated the baseline, especially when patients have low body mass and low creatinine, and may have influenced the results.
In conclusion, serum creatinine is not inferior to plasma NGAL in predicting RIFLE-F within 7 days in adult patients with severe sepsis. Nevertheless, both serum creatinine and plasma NGAL do not have good discrimination for hospital mortality. Based on these results, serum creatinine might be used first to evaluate acute renal failure and to decide on RRT initiation.
